---
title: "VK2735 in Chronic weight management: Heterogeneity of treatment effect"
description: "Formulary evidence on VK2735 in Chronic weight management: Heterogeneity of treatment effect. Topics: Subgroup assessment for semaglutide and tirzepatide in the ICER review; Race and ethnicity: representation and weight loss in incretin trials; Sex, age, and region: semaglutide 2.4 mg in SELECT; Reproductive stage: tirzepatide in women in SURMOUNT-1; 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Subgroup assessment for semaglutide and tirzepatide in the ICER review

> “We did not find evidence of major differences in the balance of benefits and risks for the following subgroups: age, sex at birth, race and ethnicity, BMI categories, use and intensity of lifestyle interventions, established CV disease, and prior bariatric surgery.”
> “Tirzepatide also demonstrated consistent percent changes in body weight from baseline versus placebo in BMI-defined subgroups (BMI <30, BMI 30-35, BMI 35-40, and BMI >40).”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.3-2"></a>

### Race and ethnicity: representation and weight loss in incretin trials

> “Although subgroup analysis did not show statistically significant differences in weight loss by sex and race/ethnicity in post-hoc analyses of the STEP trials, Black, Hispanic, and Asian participants had numerically less weight loss than White participants.”
> “Given the underrepresentation of Black and Hispanic populations in the STEP and SURMOUNT trials, additional data are needed to ascertain if there may be differences in outcome by subgroup.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.3-3"></a>

### Sex, age, and region: semaglutide 2.4 mg in SELECT

> “Women had a greater difference in mean weight loss with semaglutide versus placebo (−11.1% (95% CI −11.56 to −10.66) versus −7.5% in men (95% CI −7.78 to −7.23); P < 0.0001).”
> “There was a linear relationship between age category and degree of mean weight loss, with younger age being associated with progressively greater mean weight loss, but the actual mean difference by age group is small.”
> “Patients from Asia and of Asian race experienced slightly lower mean weight loss (estimated treatment difference with semaglutide for Asian race −7.27% (95% CI −8.09 to −6.46; P = 0.0147) and for Asia −7.30 (95% CI −7.97 to −6.62; P = 0.0016)).”

Source: [Ryan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/)

<a id="topic-2.2.2.3-4"></a>

### Reproductive stage: tirzepatide in women in SURMOUNT-1

> “In SURMOUNT‐1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001).”

Source: [Tchang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12015656/)

<a id="topic-2.2.2.3-5"></a>

### Diabetes status: tirzepatide in SURMOUNT-1, adults without diabetes

> “The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo”

Source: [Jastreboff et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35658024/)

<a id="topic-2.2.2.3-6"></a>

### Diabetes status: tirzepatide in SURMOUNT-2, adults with type 2 diabetes

> “Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively, and -3·2% (0·5) with placebo”

Source: [Garvey et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37385275/)

<a id="topic-2.2.2.3-7"></a>

### Diabetes status: semaglutide 7.2 mg in STEP UP, adults without diabetes

> “The mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg (-18·7% [SE 0·4] vs -15·6% [0·7]; estimated treatment difference [ETD] -3·1% [95% CI -4·7 to -1·6]; p<0·0001) and with semaglutide 7·2 mg versus placebo (-18·7% [0·4] vs -3·9% [0·6]; -14·8% [-16·2 to -13·4]; p<0·0001).”

Source: [Wharton et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40961952/)

<a id="topic-2.2.2.3-8"></a>

### Diabetes status: semaglutide 7.2 mg in STEP UP T2D, adults with type 2 diabetes

> “Compared with placebo, semaglutide 7·2 mg led to greater reductions in mean bodyweight (-13·2% vs -3·9%; estimated treatment difference [ETD] -9·3% [95% CI -11·0 to -7·7]; p<0·0001)”

Source: [Lingvay et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40961953/)

<a id="topic-2.2.2.3-9"></a>

### Age 65 years and older: oral orforglipron in ATTAIN-1 and ATTAIN-2

> “At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)”
> “Comparable findings were observed in participants <65 years of age.”

Source: [Horn et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453602/)

<a id="topic-2.2.2.3-10"></a>

### Subcutaneous formulation: BMI category change by baseline obesity class in VENTURE

| Baseline BMI category | VK2735 participants (n) | Placebo participants (n) | VK2735: no change in obesity class | Placebo: no change in obesity class |
| --- | --- | --- | --- | --- |
| Class III obesity | “n=35” | “n=15” | “31 %” | “87 %” |
| Class II obesity | “n=51” | “n=10” | “18 %” | “80 %” |
| Class I obesity | “n=46” | “n=8” | “26 %” | “75%” |

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="topic-2.2.2.3-11"></a>

### Diabetes status: survival after metabolic-bariatric surgery

> “In subgroup analyses, both individuals with (hazard ratio 0·409, 95% CI 0·370-0·453, p<0·0001) or without (0·704, 0·588-0·843, p<0·0001) baseline diabetes who underwent metabolic-bariatric surgery had lower rates of all-cause mortality, but the treatment effect was considerably greater for those with diabetes (between-subgroup I2 95·7%, p<0·0001).”

Source: [Syn et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33965067/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
